In a commentary led by NYU’s Orrin Devinsky, M.D., Ph.D., a global collection of investigators come to a consensus that CBD has been incompletely investigated clinically due to poor trial design (i.e., unclear dosing regimens, improper study group sizes). But with the compelling preclinical studies and patient and caregiver anecdotes, CBD is certainly worthy of rigorous clinical investigation. Those hawking non-pharmaceutical CBD products might be dismayed to learn that several of the authors are collaborators of GW Pharmaceuticals and/or conducting GW-supported drug trials.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.